Yann d’Hervé, previously Head of the Care Solutions business line in Evonik Nutrition & Care division, will assume leadership of the Health Care business line effective July 1st. His appointment underscores Evonik’s commitment to strategic leadership and innovation in the healthcare sector.
Yann d’Hervé holds an MSc in Chemistry and an MBA. Yann d’Hervé joined the former REXIM SAS (France) in 1996, where he worked in a number of different roles. REXIM is now part of the Health Care business line in Evonik. In 2004, he moved to the U.S. to join what is today’s Oil Additives business line, working as a business analyst and subsequently as Global Business Director for Wax Modifiers. In 2011, the Health Care business line was formed and d’Hervé became Vice President, Sales & Services Americas. In 2015, he assumed the role as Vice President, Global Sales & Services before moving to Germany to lead the Care Solutions business line in 2020.
Yann possesses broad expertise spanning manufacturing, finance, marketing, application technology, sales, and general management. He has managed international organizations, while being responsible for strategic alliances with key partners. Customer satisfaction and joint value creation are two cornerstones in d’Hervé’s approach to business.
Evonik Health Care partners with the world’s pharmaceutical, medical and nutritional companies to transform complexity into value. With a broad and versatile portfolio of high-quality ingredients, delivery systems and contract services, Evonik Health Care generates distinctive outcomes that advance health and well-being.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: It want to improve life today and tomorrow.
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.